Misplaced Pages

Dihydralazine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 15:15, 15 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit Latest revision as of 13:25, 25 March 2024 edit undoEcangola (talk | contribs)Extended confirmed users93,554 edits fmtTag: Visual edit 
(38 intermediate revisions by 28 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Unreferenced stub|auto=yes|date=December 2009}}
{{Redirect-distinguish|Nepresso|Nespresso}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed | Watchedfields = changed
| verifiedrevid = 414423443 | verifiedrevid = 460786592
| IUPAC_name = 4-hydrazinyl-1-hydrazinylidene-1,2-dihydrophthalazine | IUPAC_name = 4-Hydrazinyl-1-hydrazinylidene-1,2-dihydrophthalazine
| image = Dihydralazine structure.svg | image = Dihydralazine.svg
| width = 125
| image2 = Dihydralazine-3D-balls.png
| width2 = 125


<!--Clinical data--> <!--Clinical data-->
Line 11: Line 15:
| Drugs.com = {{drugs.com|international|dihydralazine}} | Drugs.com = {{drugs.com|international|dihydralazine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 --> | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD --> | legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only --> | legal_US = <!-- OTC / Rx-only -->
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
Line 24: Line 28:
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =


<!--Identifiers--> <!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = <!-- blanked - oldvalue: 484-23-1 --> | CAS_number = 484-23-1
| ATC_prefix = C02 | ATC_prefix = C02
| ATC_suffix = DB01 | ATC_suffix = DB01
Line 36: Line 40:
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9813 | ChemSpiderID = 9813
| UNII_Ref = {{fdacite|changed|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PCU411F5L6 | UNII = PCU411F5L6
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
Line 45: Line 49:
<!--Chemical data--> <!--Chemical data-->
| C=8 | H=10 | N=6 | C=8 | H=10 | N=6
| smiles = NNc1c2ccccc2C(=NN)Nn1
| molecular_weight = 190.205
| smiles = n2nc(c1ccccc1c2NN)NN
| InChI = 1/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
| InChIKey = VQKLRVZQQYVIJW-UHFFFAOYAA
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14) | StdInChI = 1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
Line 55: Line 56:
}} }}


'''Dihydralazine''' is a ]<ref name="lybrate">{{Cite web |title=Dihydralazine - Uses, Side Effects, Substitutes, Composition And More |url=https://www.lybrate.com/medicine/dihydralazine/ |access-date=2024-03-25 |website=Lybrate |language=en}}</ref> with ] properties.<ref>{{cite journal | vauthors = Stern HC, Matthews JH, Belz GG | title = Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects | journal = British Heart Journal | volume = 52 | issue = 4 | pages = 435–9 | date = October 1984 | pmid = 6477782 | pmc = 481656 | doi = 10.1136/hrt.52.4.435 }}</ref> It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally, and is available in the form of tablets.<ref name=lybrate></ref> It belongs to the ] ].<ref name=Bourreli1988>{{cite journal | vauthors = Bourreli B, Pinaud M, Passuti N, Gunst JP, Drouet JC, Remi JP | title = Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion | journal = Canadian Journal of Anaesthesia | volume = 35 | issue = 3 ( Pt 1) | pages = 242–8 | date = May 1988 | pmid = 3383316 | doi = 10.1007/BF03010617 | doi-access = free }}</ref> It has very similar effects to ].<ref name=Bourreli1988/>
'''Dihydralazine''' is an ] of the ] ].


==See also== == Side Effects ==
*]<ref name=lybrate></ref>
* ]
*Loss of Appetite<ref name=lybrate></ref>
* ]
*]<ref name=lybrate></ref>
⚫ * ]
*]<ref name=lybrate></ref>
*]<ref name=lybrate></ref>
*]<ref name=lybrate></ref>
*Increased Heart Rate<ref name=lybrate></ref>
*]<ref name=lybrate></ref>


== Contraindications ==
⚫ ==References==
Contraindications to this drug include allergic reactions to this drug or to any of its components, ischemic heart diseases, coronary artery diseases, valvular stenosis, aortic aneurysms and pericarditis. Patients who have a previous medical history of kidney dysfunctions, liver damage, heart disorders and cerebro-vascular disorders must exercise caution while taking this medicine. Dihydralazine must not be prescribed to patients who are elderly, and to breastfeeding women. Caution must be exercised while prescribing this medicine to pregnant women.<ref name=lybrate></ref>
⚫ {{Reflist|2}}

== Other Important information on intake ==
'''When ending intake''', you are recommended to withdraw gradually from this medicine, as opposed to abruptly ceasing its intake. Heartbeat problems and edema may occur as adverse effects.<ref name=lybrate></ref>

== See also ==
⚫ *]

⚫ == References ==
⚫ {{Reflist}}

== Further reading ==
*https://go.drugbank.com/drugs/DB12945
*https://www.lybrate.com/medicine/dihydralazine


{{Nonsympatholytic vasodilatory antihypertensives}} {{Nonsympatholytic vasodilatory antihypertensives}}
{{Hydrazines}} {{Hydrazines}}


⚫ ]
⚫ ]
] ]
⚫ ]
] ]
⚫ ]



{{antihypertensive-stub}} {{antihypertensive-stub}}

]
]
]

Latest revision as of 13:25, 25 March 2024

Chemical compound "Nepresso" redirects here. Not to be confused with Nespresso. Pharmaceutical compound
Dihydralazine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 4-Hydrazinyl-1-hydrazinylidene-1,2-dihydrophthalazine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.914 Edit this at Wikidata
Chemical and physical data
FormulaC8H10N6
Molar mass190.210 g·mol
3D model (JSmol)
SMILES
  • NNc1c2ccccc2C(=NN)Nn1
InChI
  • InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
  • Key:VQKLRVZQQYVIJW-UHFFFAOYSA-N
  (what is this?)  (verify)

Dihydralazine is a prescription drug with antihypertensive properties. It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally, and is available in the form of tablets. It belongs to the hydrazinophthalazine chemical class. It has very similar effects to hydralazine.

Side Effects

Contraindications

Contraindications to this drug include allergic reactions to this drug or to any of its components, ischemic heart diseases, coronary artery diseases, valvular stenosis, aortic aneurysms and pericarditis. Patients who have a previous medical history of kidney dysfunctions, liver damage, heart disorders and cerebro-vascular disorders must exercise caution while taking this medicine. Dihydralazine must not be prescribed to patients who are elderly, and to breastfeeding women. Caution must be exercised while prescribing this medicine to pregnant women.

Other Important information on intake

When ending intake, you are recommended to withdraw gradually from this medicine, as opposed to abruptly ceasing its intake. Heartbeat problems and edema may occur as adverse effects.

See also

References

  1. ^ "Dihydralazine - Uses, Side Effects, Substitutes, Composition And More". Lybrate. Retrieved 2024-03-25.
  2. Stern HC, Matthews JH, Belz GG (October 1984). "Influence of dihydralazine induced afterload reduction on systolic time intervals and echocardiography in healthy subjects". British Heart Journal. 52 (4): 435–9. doi:10.1136/hrt.52.4.435. PMC 481656. PMID 6477782.
  3. ^ Bourreli B, Pinaud M, Passuti N, Gunst JP, Drouet JC, Remi JP (May 1988). "Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion". Canadian Journal of Anaesthesia. 35 (3 ( Pt 1)): 242–8. doi:10.1007/BF03010617. PMID 3383316.

Further reading

Nonsympatholytic vasodilatory antihypertensives (C02)
Nitrovasodilator (arterioles and venules)
Hydrazinophthalazines (arterioles)
Potassium channel openers (arterioles)
Calcium channel blockers (arterioles)
Hydrazines
Stub icon

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: